256 related articles for article (PubMed ID: 26208921)
1. Modeling rheumatoid arthritis using different techniques - a review of model construction and results.
Scholz S; Mittendorf T
Health Econ Rev; 2014 Dec; 4(1):18. PubMed ID: 26208921
[TBL] [Abstract][Full Text] [Related]
2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
3. Markov modeling and discrete event simulation in health care: a systematic comparison.
Standfield L; Comans T; Scuffham P
Int J Technol Assess Health Care; 2014 Apr; 30(2):165-72. PubMed ID: 24774101
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Markov model and discrete-event simulation techniques for HIV.
Simpson KN; Strassburger A; Jones WJ; Dietz B; Rajagopalan R
Pharmacoeconomics; 2009; 27(2):159-65. PubMed ID: 19254048
[TBL] [Abstract][Full Text] [Related]
5. An empirical comparison of Markov cohort modeling and discrete event simulation in a capacity-constrained health care setting.
Standfield LB; Comans TA; Scuffham PA
Eur J Health Econ; 2017 Jan; 18(1):33-47. PubMed ID: 26715578
[TBL] [Abstract][Full Text] [Related]
6. When does economic model type become a decisive factor in health technology appraisals? Learning from the expanding treatment options for relapsing-remitting multiple sclerosis.
Noon KM; Montgomery SM; Adlard NE; Kroes MA
J Med Econ; 2018 Oct; 21(10):983-992. PubMed ID: 29923439
[TBL] [Abstract][Full Text] [Related]
7. Including adverse drug events in economic evaluations of anti-tumour necrosis factor-α drugs for adult rheumatoid arthritis: a systematic review of economic decision analytic models.
Heather EM; Payne K; Harrison M; Symmons DP
Pharmacoeconomics; 2014 Feb; 32(2):109-34. PubMed ID: 24338344
[TBL] [Abstract][Full Text] [Related]
8. Influence of tumor necrosis factor α in rheumatoid arthritis.
Kulp W; Corzillus M; Greiner W; Pientka L; Siebert U; von der Schulenburg JM; Wasem J
GMS Health Technol Assess; 2005 Dec; 1():Doc12. PubMed ID: 21289933
[TBL] [Abstract][Full Text] [Related]
9. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
Chen YF; Jobanputra P; Barton P; Jowett S; Bryan S; Clark W; Fry-Smith A; Burls A
Health Technol Assess; 2006 Nov; 10(42):iii-iv, xi-xiii, 1-229. PubMed ID: 17049139
[TBL] [Abstract][Full Text] [Related]
10. Decision analytic modeling in spinal surgery: a methodologic overview with review of current published literature.
McAnany SJ; Anwar MA; Qureshi SA
Spine J; 2015 Oct; 15(10):2254-70. PubMed ID: 26111597
[TBL] [Abstract][Full Text] [Related]
11. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
12. The clinical effectiveness and cost-effectiveness of bariatric (weight loss) surgery for obesity: a systematic review and economic evaluation.
Picot J; Jones J; Colquitt JL; Gospodarevskaya E; Loveman E; Baxter L; Clegg AJ
Health Technol Assess; 2009 Sep; 13(41):1-190, 215-357, iii-iv. PubMed ID: 19726018
[TBL] [Abstract][Full Text] [Related]
13. Matching the model with the evidence: comparing discrete event simulation and state-transition modeling for time-to-event predictions in a cost-effectiveness analysis of treatment in metastatic colorectal cancer patients.
Degeling K; Franken MD; May AM; van Oijen MGH; Koopman M; Punt CJA; IJzerman MJ; Koffijberg H
Cancer Epidemiol; 2018 Dec; 57():60-67. PubMed ID: 30317148
[TBL] [Abstract][Full Text] [Related]
14. Review of eight pharmacoeconomic studies of the value of biologic DMARDs (adalimumab, etanercept, and infliximab) in the management of rheumatoid arthritis.
Doan QV; Chiou CF; Dubois RW
J Manag Care Pharm; 2006 Sep; 12(7):555-69. PubMed ID: 16981801
[TBL] [Abstract][Full Text] [Related]
15. Cost-utility analyses of targeted immunomodulators in rheumatoid arthritis: systematic review.
Sussman M; Tao C; Patel P; Tundia N; Clewell J; Menzin J
J Med Econ; 2020 Jun; 23(6):610-623. PubMed ID: 31971039
[No Abstract] [Full Text] [Related]
16. Causal evidence in health decision making: methodological approaches of causal inference and health decision science.
Kühne F; Schomaker M; Stojkov I; Jahn B; Conrads-Frank A; Siebert S; Sroczynski G; Puntscher S; Schmid D; Schnell-Inderst P; Siebert U
Ger Med Sci; 2022; 20():Doc12. PubMed ID: 36742460
[TBL] [Abstract][Full Text] [Related]
17. Alternative decision analysis modeling in the economic evaluation of tumor necrosis factor inhibitors for rheumatoid arthritis.
Kamal KM; Miller LA; Kavookjian J; Madhavan S
Semin Arthritis Rheum; 2006 Aug; 36(1):50-60. PubMed ID: 16887468
[TBL] [Abstract][Full Text] [Related]
18. Systematic Literature Review of Economic Evaluations of Biological Treatment Sequences for Patients with Moderate to Severe Rheumatoid Arthritis Previously Treated with Disease-Modifying Anti-rheumatic Drugs.
Ghabri S; Lam L; Bocquet F; Spath HM
Pharmacoeconomics; 2020 May; 38(5):459-471. PubMed ID: 32052376
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
